Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04956809 · ClinicalTrials.gov registry record · Phase 2
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure
A Phase 2 study of HFrEF, sponsored by University of Pennsylvania.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT04956809 is a Phase 2 study of HFrEF that has completed, run by University of Pennsylvania. The registered enrollment target is 3 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04956809, a Phase 2 study of HFrEF, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Dapagliflozin 10Mg Tab
Study Locations (1)
Pennsylvania
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2021-10-22 |
| Est. Completion | 2023-06-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04956809
The ClinicalTrials.gov registry entry for NCT04956809 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HFrEF appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04956809 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04956809 about?
NCT04956809 is a clinical study titled "Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure". This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).
What is the current status of trial NCT04956809?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2021-10-22. Estimated completion is 2023-06-01.
What conditions does trial NCT04956809 study?
This clinical trial studies the following conditions: HFrEF.
What interventions are being tested in trial NCT04956809?
The interventions under investigation include: Placebo (DRUG), Dapagliflozin 10Mg Tab (DRUG).
Who is sponsoring clinical trial NCT04956809?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04956809 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.